Zymeworks Inc. (ZYME) Stock Forecast
ZYME analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 14 analysts
- Price target
- $41.21 average of analyst targets
- Upside to target
- +64.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $2.50
- 52-week range
- $16.46 – $31.05
ZYME analyst ratings
14 analystsNumber of analysts at each rating.
ZYME price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ZYME earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.15 | −$0.57 | $3.29 | −$0.26 | +928.7% | 7 |
| Current fiscal year (2026) | $0.94 | $0.25 | $1.75 | −$1.08 | +186.9% | 8 |
| Next fiscal year (2027) | $1.06 | −$1.29 | $4.17 | $0.94 | +12.5% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ZYME revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $218.3M | $4.2M | $256.4M | +690.5% | 7 |
| Current fiscal year (2026) | $289.5M | $284.9M | $293.2M | +173.2% | 8 |
| Next fiscal year (2027) | $391.1M | $289.0M | $543.1M | +35.1% | 9 |
ZYME EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ZYME revenue: reported and forecast
ZYME EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.10 | $1.39 | $2.24 | $2.07 | $2.15 | +2.6% | 1 up · 1 down |
| Current fiscal year (2026) | $1.40 | $1.17 | $1.18 | $0.89 | $0.94 | −32.9% | 1 up · 2 down |
| Next fiscal year (2027) | $0.28 | $1.29 | $1.17 | $0.87 | $1.06 | +272.1% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ZYME earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ZYME beat in 6 of 12.
What analysts expect from ZYME
14 analysts cover Zymeworks; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $41.21, 64.7% above the latest close of $25.03. Analysts expect earnings of $0.94 per share for 2026, +186.9% from a year earlier. For 2027 the average estimate is $1.06 per share on revenue of $391.1 million. Zymeworks beat the EPS estimate in 6 of the last 12 quarters.
Related: ZYME income statement, ZYME key metrics, ZYME chart. See the ZYME stock overview for the latest quote and news.
ZYME forecast FAQ
What is Zymeworks's price target?
The average analyst price target for Zymeworks is $41.21, 64.7% above the latest close of $25.03.
Is Zymeworks a buy, hold or sell?
Of 14 analysts covering Zymeworks, 12 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Zymeworks's EPS forecast?
Analysts forecast $0.94 per share for 2026 (range $0.25 to $1.75); for 2027 the estimate is $1.06.
What is Zymeworks's revenue forecast?
The average revenue estimate for 2026 is $289.5 million, growth of 173.2%; for 2027 it is $391.1 million.
When does Zymeworks report earnings?
Zymeworks is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $2.50.
Does Zymeworks usually beat earnings estimates?
Zymeworks reported EPS at or above the analyst estimate in 6 of the last 12 quarters.